Missouri Medicine review lists BPC-157 among unapproved injectables lacking human safety profiles
A narrative review in Missouri Medicine groups BPC-157 with TB-500, melanotan-II and other non-prescription injectables, stating these substances lack established human safety profiles and outlining categories of potential toxicity.
Missouri medicine · 2026 · Review · Other species · Published October 9, 2026
This page reports what published studies found. It is not medical advice, no provider-patient relationship is created by reading it, and nothing here is a recommendation to use any compound. Talk with a licensed clinician about your own situation. Read the full disclaimer.
What the review covers
This source is a narrative review article published in Missouri Medicine, not a study in people or animals; no participants or sample size are reported, and the classified species is listed as other. The abstract states that injectable peptides are increasingly used without prescriptions for cosmetic and athletic enhancement, driven by digital marketing and social media.
The authors frame the article as an effort to separate evidence-based therapeutics from what they call unproven, high-risk compounds, and to outline molecular mechanisms of toxicity associated with popular injectables used for appearance enhancement.
What it reported
The abstract places BPC-157 alongside TB-500 and melanotan-II as unapproved peptides, and alongside the veterinary anabolic steroid trenbolone and investigational triple-agonists such as retatrutide, stating that these substances lack established human safety profiles.
The review lists categories of potential risk the authors attribute to this group of substances: product contamination, manufacturing impurities, inaccurate dosing, pathological angiogenesis, carcinogenesis, cardiovascular stress, and supraphysiological hormonal signaling. The abstract presents these as potential risks rather than measured outcomes in a defined population.
By contrast, the authors write that FDA-approved peptides such as semaglutide and tirzepatide offer significant clinical benefits under medical supervision. The closing statement is directed at clinicians, who the authors say must recognize these trends and counsel patients on potential long-term health hazards.
Limitations
This is a review, so it reports no new data: there is no cohort, no control group, no randomization, and no sample size. The abstract does not state how the literature was searched or selected, so the article cannot be assessed as a systematic review or meta-analysis.
The risks named in the abstract are described as potential and are grouped across several chemically unrelated substances, so nothing in the abstract quantifies the frequency or severity of any specific harm from BPC-157 on its own. The abstract reports no dosing regimen for any compound, and no funding or author affiliation details are given in the text provided.
Regulatory context
BPC-157, also called body protection compound 157 or pentadecapeptide BPC 157, is not an FDA-approved drug for any use. This status comes from the site's regulatory review and not from the review article summarized here.
Claims and where they come from
Each statement below is followed by the passage of the source record it was checked against.
The review groups BPC-157 with TB-500 and melanotan-II as unapproved peptides that, in the authors' words, lack established human safety profiles.
“These unregulated substances-including the veterinary anabolic steroid trenbolone, investigational triple-agonists like retatrutide, and unapproved peptides such as BPC-157, TB-500, and melanotan-II-lack established human safety profiles.”
The authors list potential risk categories including contamination, impurities, inaccurate dosing, pathological angiogenesis and carcinogenesis.
“Their use introduces severe potential risks, including product contamination, manufacturing impurities, inaccurate dosing, pathological angiogenesis, carcinogenesis, cardiovascular stress, and supraphysiological hormonal signaling.”
The abstract attributes rising non-prescription use of injectable peptides to digital marketing and social media.
“Injectable peptides are increasingly used without prescriptions for cosmetic and athletic enhancement, driven by digital marketing and social media.”
The article is framed as a review distinguishing approved therapeutics from compounds the authors call unproven and high-risk.
“This review differentiates evidence-based therapeutics from unproven, high-risk compounds and outlines the molecular mechanisms of toxicity associated with popular "looksmaxxing" injectables.”
The authors contrast these substances with approved peptides such as semaglutide and tirzepatide used under medical supervision.
“While evidence-based, FDA-approved peptides like semaglutide and tirzepatide offer significant clinical benefits under medical supervision, an expanding illicit market provides easy access without a prescription to many unapproved experimental drugs.”
The closing recommendation is addressed to clinicians rather than to consumers.
“Clinicians must recognize these trends, and counsel patients on potential long-term health hazards of these potent agents.”
Common questions
Does this article report any doses of BPC-157?
No. The abstract states no regimen, route, or frequency for BPC-157 or any other substance it discusses. It lists inaccurate dosing as one of the potential risks it attributes to unregulated injectables.
Is this new experimental data on BPC-157?
No. The source is a review article. It reports no participants, no animals, and no sample size, and the abstract does not describe a search strategy or pooled analysis.
What risks does the abstract name?
It lists product contamination, manufacturing impurities, inaccurate dosing, pathological angiogenesis, carcinogenesis, cardiovascular stress, and supraphysiological hormonal signaling as potential risks across the group of substances it covers.
Does the review say BPC-157 causes these harms?
The abstract describes them as severe potential risks tied to a group of unregulated substances collectively, and states that these substances lack established human safety profiles. It does not report measured outcomes attributed specifically to BPC-157.
Source
- 1.Dangers of Injectable Peptides and Other Unregulated "Biohacking" Drugs — Missouri medicine (2026)ReviewotherPMID 42757290